Shedding Light on How Tumors Become Resistant to Immunotherapy

News   Jul 26, 2017 | Original story from University of Zurich

 
Shedding Light on How Tumors Become Resistant to Immunotherapy

The epigenetic control protein Ezh2 plays a central role in how cancer cells develop resistance. (Bild: D. Zingg, UZH)

 
 
 

RELATED ARTICLES

XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery Services

News

XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.

READ MORE

BioAscent Establishes Integrated Drug Discovery Services Offering

News

Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.

READ MORE

Lab Innovations returns to the NEC, Bimingham , UK

News

Save the date for the UK’s only lab-dedicated exhibition showcase!

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Biopharma Genomics Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE